---
title: "TD Cowen Sticks to Its Buy Rating for Sera Prognostics (SERA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279718017.md"
description: "TD Cowen analyst Daniel Brennan has reaffirmed a Buy rating for Sera Prognostics (SERA), with shares closing at $1.91. Brennan, who specializes in the Healthcare sector, has an average return of 14.6% and a 44.93% success rate on his stock recommendations. The consensus for Sera Prognostics is a Moderate Buy according to TipRanks."
datetime: "2026-03-19T03:55:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279718017.md)
  - [en](https://longbridge.com/en/news/279718017.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279718017.md)
---

# TD Cowen Sticks to Its Buy Rating for Sera Prognostics (SERA)

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Buy rating on Sera Prognostics. The company’s shares closed yesterday at $1.91.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Brennan covers the Healthcare sector, focusing on stocks such as Agilent, Myriad Genetics, and 10x Genomics. According to TipRanks, Brennan has an average return of 14.6% and a 44.93% success rate on recommended stocks.

Sera Prognostics has an analyst consensus of Moderate Buy.

### Related Stocks

- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SERA.US](https://longbridge.com/en/quote/SERA.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md)
- [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)](https://longbridge.com/en/news/286443716.md)